U.S.-Based Magrathea Launches Next-Gen Magnesium Production Technology, Advances Plans to Scale
Important step to build a scalable technical model and garner data to deploy technology commercially to support the manufacturing of virtually all of America's key defense platforms
Implementing technical initiatives to further improve cost and environmental efficiencies of proven technology
Technology enables American companies to secure a reliable critical mineral supply to counter trade policies and export controls
SAN FRANCISCO, May 28, 2025--(BUSINESS WIRE)--Magrathea ("Magrathea" or the "Company"), a technology company that produces magnesium metal from seawater, today announced the launch of its next-generation magnesium chloride electrolyzer, a machine that uses electricity to split magnesium salts to make magnesium metal, at its pilot facility in Oakland, California. This milestone is a crucial step to advance the technical and data framework for a future scaled plant. Additionally, the project strategically positions Magrathea's technology to provide American companies with access to U.S.-based critical mineral supply chains amid shifting trade policies and export controls.
"Magnesium is one of the most important critical materials, but NATO countries face a dire shortage of non-China supply," Alex Grant, CEO of Magrathea, said. "Western nations must view this supply crisis as a national security emergency."
"At our core, Magrathea's innovative technology revitalizes a proven process with our own twist for considerable efficiency improvement and expense reduction," Mr. Grant continued. "We expect to reduce the technology's operating expenses to make it cost-competitive with alternative production methods that exist today, including in China. Magrathea is in conversations with several major defense, chemical and mining industrial players to form a strategic partnership to scale up our technology as the first new commercial-scale magnesium electrolyzer in the United States in the past 50 years."
Over the coming months, Magrathea will use data gathered from the pilot-scale electrolyzer to create a scalable technical model aimed at achieving the highest efficiencies from both environmental and economic perspectives. The Company will focus on obtaining process data, minimizing total electricity use, recycling energy in strategic ways and optimizing the dehydration process, which offers the biggest opportunity for cost reduction in the electrolytic magnesium metal production process. These technical efforts are expected to significantly reduce the carbon footprint and operating expenditure of future commercial plants. The data and key processing learnings are also expected to help streamline permitting processes for future facilities given the inherent environmental benefits of the technology.
Magrathea and Magnesium Highlights
The "Gateway Metal": Magnesium unlocks a wide range of applications, such as stiffening aluminum in alloys, steel making, nuclear inputs, automotive, aerospace, and next-generation defense applications.
Solving a National Security Emergency: Russia and China currently control 90% of the global primary magnesium supply with no significant producer in any NATO country.
First Mover Advantage: Magrathea is the most advanced new producer of magnesium metal with significant intellectual property including patents and trade secrets.
Existing Operations: Magrathea's operational pilot plant in California can produce 4,000 pounds of magnesium annually at full capacity.
Low Operational Expense: Magrathea's technology demonstrates competitive operating costs, leveraging abundantly available seawater and renewable energy as feedstock.
Carbon Neutral: Technology produces 0 kg CO2 eq./kg magnesium compared to over 40 kg CO2 eq./kg magnesium with the incumbent Chinese process, which is expected to further streamline permitting processes for future scaled facilities.
Scalable to Meet Demand: Magrathea – in partnership with a strategic partner – plans to deploy its technology at a scaled facility by 2027 to produce up to 2 million pounds of magnesium per year, enough to support the equivalent production of thousands of Black Hawk helicopters annually.
Significant Commercial Traction: Magrathea has signed agreements with more than 25 companies, including 10 connected to the U.S. defense industry, an offtake agreement with a global automaker, and a resource supply agreement with Cargill.
Additional Market Opportunities: In addition to magnesium, Magrathea produces chloride co-products, which have a wide range of end-markets such as bleach, to unlock more value and improve project economics.
Strong Engineering Partnership: Magrathea is collaborating with Sedgman Novopro, an engineering firm specialized in mining and mineral processing, to support its scale-up engineering and design program.
Backed By Marquee Investors: Technology is backed by credible investors, including the U.S. Department of Defense, Capricorn, VoLo Earth, Exor Ventures, Sam Altman, and leaders at Glencore, Mitra Chem, Tesla, and many more.
About Magrathea
Magrathea is a technology company based in California that has developed a process for making magnesium metal from seawater and brines to help the West solve its magnesium shortage. Magnesium is essential for a wide range of applications such as stiffening aluminum in alloys, steel making, inputs for nuclear applications, automotive, aerospace, and next-generation defense applications. The company's technology is expected to be the largest primary production solution across NATO countries by 2030. For more information, please visit https://www.magratheametals.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250528694331/en/
Contacts
Mediamedia@magratheametals.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
43 minutes ago
- The Hill
Food and Drug Administration staff cuts may hinder US biomedical innovation
President Trump has rightly emphasized restoring America's economic and strategic independence — from reshoring pharmaceutical production to cutting regulatory red tape. But not all reforms are created equal. Recent restructuring efforts at the Food and Drug Administration may have been well-intentioned, but they risk undermining the very innovation and domestic capacity the president seeks to promote. In March, Health and Human Services Secretary Robert F. Kennedy Jr. announced a sweeping reorganization of the agency, which in part included the elimination of 3,500 full-time employees at the Food and Drug Administration — many of them senior scientific staff and experienced regulators who served as institutional pillars across drug review divisions. While we all support government efficiency and the secretary's efforts to create a gold-standard regulatory agency, the loss of this institutional memory risks hobbling the expedited pathways that small biotech firms rely on to deliver therapies for rare and life-threatening diseases. Unfortunately, the impact of these cuts is not theoretical. The Wall Street Journal has reported that some biotech firms have had to delay or cancel clinical trials due to lack of timely Food and Drug Administration guidance. One California biotech firm facing unpredictable delays has even turned to European regulators to move forward with a clinical trial — effectively offshoring American capital, investment and jobs. Others have reported receiving conflicting and confusing feedback from inexperienced FDA staff or no response at all on time-sensitive requests. But such issues don't just affect companies; they hurt patients, too. Innovation in gene therapies, cancer immunotherapies, and treatments for rare diseases depend on regulatory clarity and speed. Without senior staff to help clarify agency positions, decisions are either delayed or driven by less-experienced personnel unfamiliar with long-standing scientific standards. It's no surprise then that over 200 biotech CEOs, patient advocates and investors — many of them strong supporters of FDA modernization — have expressed their concerns in a letter to Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy (R-La.). As a former member of Congress who sat on the Appropriations subcommittee overseeing the FDA, I have long supported targeted reforms to make the agency more nimble and responsive. But there is a fine line between streamlining operations and cutting the institutional capacity necessary to do the job. Removing experienced drug reviewers before an adequate backup plan can be put into place not only jeopardizes U.S. safety standards but also undermines our competitive edge. This matter is not merely a domestic problem; it's a global race. Since 2014, the number of biomedical drugs under development in China has grown twelvefold. Meanwhile, innovation in the U.S. has remained relatively flat. If trends continue, China could match or surpass the U.S. in biomedical innovation within the decade. We have seen this movie before — in semiconductors, in telecommunications, in clean energy. We cannot afford to let biotech go the same way. The Trump administration's tariff policy was designed to bring pharmaceutical manufacturing back to U.S. shores. But how can we expect capital to stay in the U.S. if our regulatory infrastructure cannot deliver? Delays and unpredictability at the FDA don't just slow down science — they push investors to look elsewhere. Even the user fee system — critical to funding timely drug reviews and a source of government revenue — has been impacted by the reduction in force. Staff who oversaw the reauthorization of the Prescription Drug User Fee Act have been laid off, raising questions about whether the agency will even be able to continue to collect user fees and whether these government cuts will actually end up costing taxpayers in the long run. Of course, Kennedy has long been a vocal advocate for health reform. His Make America Healthy Again agenda's focus on combatting chronic diseases and enhancing nutritional standards deserves attention. His focus for such reform is where his background and passion can lead to meaningful improvements. But when it comes to regulating complex biologics and therapeutics, we must be careful about taking actions that could inadvertently stymie scientific progress. President Trump's vision for American self-reliance will only succeed if it's built on a foundation of regulatory competence and stability. Swift actions should therefore be taken to restore the FDA's core functions, rehire critical staff and unfreeze the hiring of roles essential to America's leadership in biomedical science. The stakes — for patients, for innovation and for national security — are simply too high to ignore. John T. Doolittle is a former member of Congress who served on the Agriculture, Rural Development, FDA, and Related Agencies subcommittee of the Committee on Appropriations.
Yahoo
44 minutes ago
- Yahoo
Cyberway Product Innovation Platform: Empowering Enterprise Innovation Processes and Building Exceptional Product Strength
GUANGZHOU , June 22, 2025 /PRNewswire/ -- In the fiercely competitive FMCG market, only efficient innovation can create a true competitive edge. As consumer preferences change rapidly and the market environment remains uncertain, how can companies precisely identify needs, execute efficiently, and continuously optimize their strategies? The Cyberway Product Innovation Platform empowers FMCG enterprises to achieve sustainable growth by providing powerful capabilities in pre-planning insight, in-process control, and post-launch analytics—ultimately enabling the development of exceptional product strength. Before: AI-Powered Foresight for Accurate Market Opportunity Detection AI Opportunity Discovery: Real-time industry data, user behavior, and competitor insights are captured to automatically identify blue ocean markets and unmet needs—fueling inspiration for new product planning. Accelerate Opportunity Capture: Shorten market research cycles and improve speed and accuracy of opportunity identification. AI-Driven Product Definition: Using opportunity and competitor analysis, combined with internal product knowledge bases, the system intelligently generates product concepts, optimizes configurations, and refines packaging and formulas. Agile Response: Ensure product design closely aligns with market needs and competition, allowing rapid focus on core value and improving product-market fit. End-to-End User Demand Management: A comprehensive demand management framework tracks records, statuses, and feedback, aggregating omnichannel voice of customer with AI to identify high-value & Accurate: By realizing and verifying demand in closed-loop cycles, continuously refine product performance, minimize resource waste, and pave the way for the next breakout product. During: Efficient Execution to Deliver Outstanding Products Scientific Project Management System: Integrates visual dashboards, all-in-one workbenches, and real-time notifications via Feishu, WeCom, and DingTalk for full project transparency and synchronized decision-making across teams. Core Value: Reduce communication overhead, improve collaboration efficiency, and prevent project delays. Standardized Project Workflow: Based on industry templates and task libraries, enabling tiered and structured project management tailored to channel requirements. Flexible Control: Guarantees high-quality delivery while allowing adaptive workflows, ensuring key tasks succeed the first time. Cross-Functional Online Collaboration: Integrates marketing, go-to-market, and product workflows to shorten timelines. Interlocked nodes require mutual confirmation to ensure stability and avoid cost waste. Key Feature: Enables synergistic cooperation across departments for performance greater than the sum of its parts. AI Marketing: Tracks competitor strategies and social trends in real time, dynamically generating targeted content and pricing strategies using internal knowledge. Efficient & Agile: Accelerates creative production and drives an integrated "strategy-content-pricing" engine for rapid market response. Online Knowledge Repository: A dedicated enterprise R&D knowledge base aggregating key data such as risk warnings, solutions, and technical documentation. Significant Boost: Empowers faster troubleshooting and prevents redundant errors in R&D. Comprehensive Quality Control System: Embeds IPD checkpoints and technical reviews to govern key milestones; incorporates risk management for prevention, monitoring, and post-analysis. Ultimate Goal: Ensure high-quality project delivery while minimizing potential risks. After: Data-Driven Innovation Strategy Optimization Project Review: Compare project baselines with actual execution to deeply analyze quality, timeline, and cost performance. Deeper Insights: Identify key factors that influence project success. Go-to-Market Tracking: Monitor GMV trends across e-commerce platforms, VOC on social media, and promotional campaign outcomes to pinpoint growth opportunities and risks, driving agile strategy iteration. Advanced Capabilities: Fuel product iteration and innovation, providing a core foundation for the next-generation breakout product. Data Asset Management: Leverages delivery data and gate review points to auto-update master product data, creating a unified view with field supplementation and relationship validation. Long-Term Value: Enables full-lifecycle product data management, enhancing both data quality and business utility. The Cyberway Product Innovation Collaboration Platform is a powerful enabler for FMCG enterprises to enhance product innovation with AI, reduce waste, shorten R&D cycles, and create market bestsellers. From ideation to launch and ongoing optimization, the platform empowers excellence at every stage—allowing businesses to stand out in an intensely competitive landscape. We look forward to partnering with more brands to explore new ways of innovation and co-create the next market blockbuster! Website: Email：Marketing@ View original content: SOURCE Cyberway Information Technology Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
an hour ago
- Newsweek
IndyCar Unveils the 2028 Race Car
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. IndyCar announced the new car for the 2028 season, which will be ready for testing in 2026. The American racing series revealed the new race car while at the Road America track ahead of the XPEL Grand Prix. Dallara is producing the new chassis for the car, continuing as the exclusive chassis for IndyCar as it has since 2008. The series officials plan on the new design improving the racing throughout all four track types and pushing the car's development further. "The time has come for a new NTT INDYCAR SERIES chassis," INDYCAR President Douglas Boles said in a statement. "The DW12 served the series so well, as it provided a combination of phenomenal, wheel-to-wheel racing and critical enhancements to safety. "But recent significant updates to the car - from the aeroscreen to the hybrid power unit - have helped advance the need for a completely new car. "We are pleased by what our engineers and Dallara have collaboratively designed and believe it will appeal to the fans and paddock while also upholding our standards of safety and enhancing INDYCAR's on-track competition well into the future." The 2028 car features a projected weight of 85-100 pounds compared to the current model. The engine is going to become a 2.4-liter twin-turbocharged V-6 internal combustion engine, which should be more powerful. Scott McLaughlin, driver of the #3 Dex imaging Team Penske Chevrolet drives during the NTT INDYCAR Firestone Grand Prix of St. Petersburg on March 02, 2025 in St Petersburg, Florida. Scott McLaughlin, driver of the #3 Dex imaging Team Penske Chevrolet drives during the NTT INDYCAR Firestone Grand Prix of St. Petersburg on March 02, 2025 in St Petersburg, Florida. Photo by Miguel will create the power supply as it has since 2000. They designed the engine to be 25 pounds lighter and to use more electrical power. The new model is still not set, as the designers and engineers are still rounding out the rough edges of the design. IndyCar stated that further details and renderings of the design are yet to come. It is unclear when the timeline for its unveiling will. While the features and promise of the new car sound nice, there is still much to be learned from testing to see if it can deliver better racing than the current generation of cars. IndyCar's European competitor, Formula 1, introduced a new set of regulations in 2022, which promised better racing, but the cars are creating more dirty air than ever, making it harder for cars to follow others. If they manage to develop a meaningful improvement over the current car that races better across the different tracks, the series' unique tracks could shine more, setting it apart from any other motorsport in the world and continuing to compete with F1.
